🔗 Share this article WHO Raises Alert Over Critical Shortage of Weight-Loss Jabs Less than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it releases its initial guidance on the therapies. With more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. According to projections, over two billion could be living with obesity by 2030 if no action is taken. "The new guidelines recognises that obesity is a long-term condition that can be addressed with comprehensive and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the injections that can help people shift considerable weight, notes the body. GLP-1 Therapy Supply Crisis Despite the current most optimistic scenario, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The recommendation urges nations and manufacturers to increase availability, by approaches including voluntary licensing. A patent on semaglutide – the main component of a leading brand – is due to expire in multiple countries in 2026. How Obesity Drugs Operate These medications imitate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals reduce food intake. Patients typically see weight reduction in the initial weeks of beginning the regular doses. Studies indicates patients may put most of the weight back on a year later of discontinuing the drug, as their normal hunger resume. To be carrying excess weight raises your chance for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and some cancers. Obesity concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.
Less than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it releases its initial guidance on the therapies. With more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. According to projections, over two billion could be living with obesity by 2030 if no action is taken. "The new guidelines recognises that obesity is a long-term condition that can be addressed with comprehensive and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the injections that can help people shift considerable weight, notes the body. GLP-1 Therapy Supply Crisis Despite the current most optimistic scenario, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The recommendation urges nations and manufacturers to increase availability, by approaches including voluntary licensing. A patent on semaglutide – the main component of a leading brand – is due to expire in multiple countries in 2026. How Obesity Drugs Operate These medications imitate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals reduce food intake. Patients typically see weight reduction in the initial weeks of beginning the regular doses. Studies indicates patients may put most of the weight back on a year later of discontinuing the drug, as their normal hunger resume. To be carrying excess weight raises your chance for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and some cancers. Obesity concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.